Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VNDA
SELLVanda Pharmaceuticals Inc. · Healthcare · United States · $312M · Avg Vol: $5M/d
COMPANY DESCRIPTION
Vanda Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Its competitive moat is built upon its proprietary, approved products like Hetlioz for non-24-hour sleep-wake disorder and Fanapt for schizophrenia, addressing significant unmet medical needs in niche patient populations. Vanda maintains a focused R&D pipeline aimed at expanding its CNS franchise.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 254.4M | 192.6M | 198.8M | 216.1M | -5.3% | 217.8M | 262.1M | 356.5M | 28.4% |
| EPS | 0.11 | 0.04 | -0.33 | -3.74 | -63.6% | -3.97 | -2.27 | -0.77 | — |
| Shares | 56.8M | 57.5M | 58.3M | 59.1M | +4.1% | 60.1M | — | — | — |
| Debt | 11.1M | 9.4M | 12.4M | 12.6M | 4.2% | 13.1M | — | — | — |
| Equity | 527.2M | 544.9M | 538.5M | 327.2M | -14.7% | — | — | — | — |
| Op CF | 32.0M | 12.8M | -15.8M | -109.4M | -60.0% | -126.5M | — | — | — |
| Inv CF | 49.9M | -12.1M | -17.4M | 94.9M | — | — | — | — | — |
| Fin CF | 0.7M | 0 | -0.2M | -2.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VNDA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VNDA | Vanda Pharmaceuticals Inc.(you) | $312M | 26 | SELL |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $308M | 27 | SELL |
| FATE | Fate Therapeutics, Inc. | $281M | 26 | SELL |
| PRLD | Prelude Therapeutics Incorporated | $305M | 23 | SELL |
| PALI | Palisade Bio, Inc. | $339M | 28 | SELL |
| SABS | SAB Biotherapeutics, Inc. | $268M | 28 | SELL |
| OABI | OmniAb, Inc. | $294M | 30 | SELL |
| ENTA | Enanta Pharmaceuticals, Inc. | $372M | 24 | SELL |
| PRTC.L | PureTech Health plc | $421M | 27 | SELL |
| LRMR | Larimar Therapeutics, Inc. | $416M | 25 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%